ArticleScience, technology & human values2017
Accelerating Innovation in the Creation of Biovalue: The Cell and Gene Therapy Catapult.
Article in Science, technology & human values, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Organoids at the forefront of global health: accelerated research and ethical implications in the cases of Zika and COVID-19.Global public health · 2025Article
- Suitable characteristics in the selection of human allogeneic chondrocytes donors to increase the number of viable cells for cartilage repair.Cell and tissue banking · 2023Article
- Quantification of bacterial adhesion to tissue in high-throughput kinetics.Biology methods & protocols · 2023Article
- Reimagining Health as a 'Flow on Effect' of Biomedical Innovation: Research Policy as a Site of State Activism.Minerva · 2022Article
- Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective.Frontiers in medicine · 2022Article
- Stem cell translational medicine: The Tianjin model revisited.Stem cells translational medicine · 2021Article
- Cell therapy for cartilage repair.Emerging topics in life sciences · 2021Review
- Accomplishing an adaptive clinical trial for cancer: Valuation practices and care work across the laboratory and the clinic.Social science & medicine (1982) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of regenerative medicine (RM) has considerable therapeutic promise that is proving difficult to realize. As a result, governments have supported the establishment of intermediary agencies to "accelerate" innovation. This article examines in detail one such agency, the United Kingdom's Cell and Gene Therapy Catapult (CGTC). We describe CGTC's role as an accelerator agency and its value narrative, which combines both "health and wealth." Drawing on the notion of sociotechnical imaginaries, we unpack the tensions within this narrative and its instantiation as the CGTC cell therapy infrastructure is built and engages with other agencies, some of which have different priorities and roles to play within the RM field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.